George Poiani, MD
Pulmonary Disease · Bridgewater, NJNPI 1881654754
Payments from drug & device makers
Across 1,059 payments — averaging $16.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Actelion Pharmaceuticals US, Inc.$2K
- Boehringer Ingelheim$2K
- AstraZeneca$2K
- Grifols USA, LLC$887
- Sanofi$713
- plus $7K from 34 others
What the payments were for
- Consulting fees$5753%
- Speaking & faculty fees$1251%
- Food & beverage$15,89794%
- Education$3952%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 249 | $3,035 |
| Actelion Pharmaceuticals US, Inc. | 104 | $1,815 |
| Boehringer Ingelheim | 106 | $1,594 |
| AstraZeneca | 76 | $1,571 |
| Grifols USA, LLC | 57 | $887 |
| Sanofi | 43 | $713 |
| Bayer | 14 | $684 |
| Mallinckrodt Hospital Products Inc. | 38 | $640 |
| United Therapeutics Corporation | 32 | $594 |
| Philips North America LLC | 34 | $521 |
| Mylan Specialty L.p. | 32 | $512 |
| Regeneron Healthcare Solutions, Inc. | 23 | $397 |
| Novartis | 27 | $387 |
| Axsome Therapeutics, Inc. | 26 | $356 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $333 |
| Jazz Pharmaceuticals Inc. | 24 | $331 |
| Amgen | 20 | $323 |
| Insmed, Inc. | 12 | $307 |
| Pfizer | 18 | $285 |
| ANI Pharmaceuticals, Inc. | 15 | $266 |
| E.r. Squibb & Sons, L.L.C. | 12 | $175 |
| Teva Pharmaceuticals USA, Inc. | 13 | $169 |
| Inspire Medical Systems, Inc. | 6 | $155 |
| Vifor Pharma, Inc. | 9 | $151 |
| Covis Pharma GmbH | 10 | $133 |
| Verona Pharma, Inc. | 7 | $122 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Genentech USA, Inc. | 4 | $63 |
| Circassia Inc. | 5 | $61 |
| Shire North American Group Inc | 4 | $52 |
| Merck | 3 | $47 |
| Johnson & Johnson | 3 | $42 |
| Pulmonx Corporation | 2 | $37 |
| Viatris Specialty LLC | 2 | $33 |
| Gilead | 2 | $25 |
| CSL Behring | 1 | $25 |
| BD | 1 | $25 |
| Baxter Healthcare | 1 | $17 |
| Resmed Corp | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,992 in reported general payments places this provider in the 85th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 200 | $251,204 |
| OpsumitMacitentan | 13 | $160,671 |
| Spiriva RespimatTiotropium Bromide | 74 | $71,163 |
| Breo ElliptaFluticasone/Vilanterol | 93 | $65,967 |
| Dupixent SyringeDupilumab | 13 | $48,356 |
| Arnuity ElliptaFluticasone Furoate | 99 | $46,426 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 44 | $38,675 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 39 | $26,585 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $9,166 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 16 | $8,261 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 173 | $8,244 |
| Montelukast Sodium | 417 | $6,545 |
| Proair RespiclickAlbuterol Sulfate | 20 | $2,935 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 15 | $2,905 |
| Roflumilast | 19 | $2,420 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta, Incruse Ellipta | $3,035 | $411,438455 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $1,815 | $160,67113 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $1,594 | $97,749113 claims |
| AstraZenecaBevespi Aerosphere | $1,571 | $8,26116 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $169 | $2,93520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Bridgewater
- Jack LeeBridgewater$21K
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.